Guardant Health
-43%
est. 2Y upside i
Rank
#3163
Sector
Biotechnology
Est. Liquidity
~2Y
Data Quality
Data: MediumThe expected upside over 2 years is -42.6%, indicating poor risk/reward for a job candidate.
Last updated: July 19, 2026
If Guardant Health maintains current multiple of ~18x due to FDA approvals for Shield screening and strong market position, exit value could reach $29.7B, yielding 43.5% gross upside. After 20% dilution, net upside 23.5%.
Multiple contracts to 10x forward revenue as growth slows, exit value $16.5B (20% decline). With 20% dilution, net downside 40%.
Multiple compresses to 5x on competitive pressure and slower adoption; exit $8.25B (60% decline). After dilution, net downside 80%.
Preference Stack Risk
lowFunding Intensity
269%Total preferred funding $557M vs current valuation $20.7B, so low preference overhang.
Dilution Risk
highGiven high capital intensity and lack of profitability, a capital raise is likely, potentially diluting existing shareholders by ~20%.
Secondary Liquidity
activeShares are publicly traded on NASDAQ, providing immediate liquidity post-vesting.
Last updated: July 3, 2026
Questions to Ask at the Interview
Strategic questions based on Guardant Health's data — designed to show you've done your homework.
- 1
“How does Guardant Health plan to achieve profitability and reduce cash burn given current operating losses?”
- 2
“What is the competitive advantage of Shield over Natera's Signatera and other screening tests?”
- 3
“How do you assess the risk of multiple compression as the company matures?”
Community
Valuation Sentiment
Our model estimates -43% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.